500 patients67,039 observations150 daysLIVE

Patient P-03160

Synthetic patientONX-7 · Day 106 · 65–74 · M · baseline S18Open companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
52%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S18
  2. Day 61 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 102 GI-04 recommendedGI Support Protocol GI-04
  4. Day 103 Patient declinedNot now

What changed?

Trajectory began diverging from predicted response on Day 61.

Primary contributors, last 14 days
  • GI instability+14
  • Nutritional resilience-10
  • Treatment adherence-9
  • Inflammatory activity+6
  • Toxicity-4

What helped?

  • GI Support Protocol GI-04Day 102
    Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
51%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 84% showed improvement
  • median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 32/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 70
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 44
  • Drug metabolism and exposure 40
    • DNACYP2D6 poor metabolizer → higher exposure
  • Mucosal barrier integrity 30
    • MicrobiomeAkkermansia low → thinner mucus layer
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 3.1 · butyrate capacity 32/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
48 ms
Sleep
7.3 h
Steps
8,575
Resting HR
70 bpm
Daily log: GI score 44, nutritional resilience 46, adherence 84.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0329246%S1462
P-0302744%S2062
P-0322143%S06GI-04no change64
P-0337843%S1059
P-0340543%S1662
P-0312040%S1461
P-0328740%S1755
P-0334640%S17GI-04improved71
P-0306438%S1050
P-0310138%S1565
P-0310938%S2063
P-0315438%S1653